Loading news...
CSL (OTCMKTS:CSLLY - Get Free Report) and Ascentage Pharma Group International (NASDAQ: AAPG - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Volatility and Risk CSL has a beta
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities Governor Pritzker, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy KING OF PRUSSIA, Pa., March 9, 2026 /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
After losing some value lately, a hammer chart pattern has been formed for CSL Limited (CSLLY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript
CSL Limited (CSLLY) Discusses Leadership Transition and Appointment of Interim CEO Transcript
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. CSL's vaccine business volatility and slow margin recovery, especially at CSL Behring, have weighed on share price and profitability since COVID-19. Management plans to demerge CSL Seqirus by FY 2026, aiming to address earnings volatility, and refocus on core plasma and kidney disease therapies.
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over.
Carlisle Companies is well-positioned to benefit from a projected rebound in U.S. residential construction driven by lower interest and mortgage rates in 2026. CSL's revenue mix, with 74% from construction materials and strong execution, supports optimism for earnings and EPS outperformance as housing demand recovers. Despite recent revenue volatility, CSL maintains profitability and market leadership, trading at a P/S of 3.12x, which appears undervalued relative to peers.
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption KING OF PRUSSIA, Pa. , Dec. 7, 2025 /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) in adults living with hemophilia B.
Carlisle Companies remains a Buy, with a target price lowered to $358 (10% upside) due to more conservative financial assumptions. CSL's Q3 results were mixed, with stable revenue supported by acquisitions and re-roofing, but margins declined more than expected. Aggressive share buybacks and dividend hikes signal management's confidence in CSL's undervaluation and strong capital return commitment.
CSL Limited (OTCQX:CSLLY) Analyst/Investor Day November 4, 2025 6:00 PM EST Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Paul McKenzie - MD, CEO & Executive Director Dave Ross - Senior VP & GM of Seqirus Presentation Fiona Mead Company Secretary & Head of Corporate Governance Hello. I'm Fiona Mead, CSL's Company Secretary.
Carlisle Companies Incorporated (NYSE: CSL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have issued a buy recommendation on the company.
Asset Management One Co. Ltd. trimmed its position in Carlisle Companies Incorporated (NYSE: CSL) by 3.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,314 shares of the conglomerate's stock after selling 673 shares during the period. Asset Management One
CSL Limited (OTCQX:CSLLY) Shareholder/Analyst Call October 27, 2025 7:01 PM EDT Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Brian McNamee Paul McKenzie - MD, CEO & Executive Director Brian Daniels Cameron Price Megan Clark Conference Call Participants Phoebe Rountree Presentation Fiona Mead Company Secretary & Head of Corporate Governance Good morning, ladies and gentlemen. We still have some people registering, but we always start our Board meetings on time at CSL.
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA , Oct. 26, 2025 /PRNewswire/ -- CSL's base fractionation facility in Broadmeadows, Australia has been recognised as the Overall Winner of the 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE). Purpose-built to optimise the production of plasma-derived therapies for conditions such as immunodeficiencies, neurological disorders, and burns, the Broadmeadows facility combines cutting-edge technologies with a pioneering hybrid manufacturing platform.
Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based quadrivalent vaccines (QIVe) in the prevention of test-confirmed influenza during the 2023/24 U.S. season for populations six months to 64 years. 1 Consistent rVE results were observed for pediatric, adult, outpatient and high-risk subgroups.